Thimmaiah Chendrimada
Founder Able Sciences
Seminars
Thursday 28th May 2026
Panel: Contrasting Circular vs. Self-Amplifying RNA to Match Modalities to Use-Cases
9:00 am
- Weigh strengths and trade-offs in potency, durability, manufacturability, and safety to guide platform decisions
- Compare fit-for-purpose advantages across CAR-T, protein replacement, combination therapies, autoimmune, and CNS applications to reduce risk
- Define where each modality delivers a strategic edge and where constraints limit applicability for smarter portfolio planning
Thursday 28th May 2026
Advancing Multi-Gene RNA Therapies to Unlock Durable In-Vivo CAR-T Treatments for Eosinophilic Conditions
1:30 pm
- Enable deeper, multi-pathway disease control in eosinophilic indications by using multi-gene RNA constructs that co-deliver multi-CARs and cytokine payloads
- Achieve durable, low-immunogenic expression suitable for repeat dosing through a synthetic RNA architecture optimized for chronic therapeutic applications
- Leverage modular multi-gene RNA design to support versatile therapeutic strategies and maintain flexibility for future development needs
